A pilot study to investigate cardiac adverse effects of ropivacaine using local infiltration anaesthesia (LIA) technique during total hip arthroplasty (THA).

A pilot study to investigate cardiac adverse effects of ropivacaine using local infiltration anaesthesia (LIA) technique during total hip arthroplasty (THA). - CaRoH

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON38715

Enrollment

Registered

2013-05-26

Start date

2013-09-17

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Total Hip Artroplasty (THA) / total hip replacement

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients 18 years and older and scheduled for THA in Reinier de Graaf hospital.

Exclusion criteria

Exclusion criteria: Allergy for ropivacaine. Moderate or severe cardiac disease, bronchial asthma (severe valave insuffiency, angina pectoris 2/4 or more, congestive heart failure, rhythmic disorder).

Design outcomes

Primary

Measure	Time frame
The primary outcome is QRS widening (delta QRS) and delta QTc-intervals measured with a 24 hour Holter ECG compared to baseline ECG.	—

Secondary

Measure	Time frame
Secondary study outcomes are bradycardia and/or tachycardia, and/or ST-elevation compared to basaeline ECG.	—

Countries

Netherlands

Outcome results